Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Sales and Divestitures (2017 - 2025)

Aclaris Therapeutics has reported Gains from Sales and Divestitures over the past 9 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $1.5 million for Q4 2025, up 4.37% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 4.37% YoY), and the annual figure for FY2025 was $1.5 million, up 4.37%.
  • Gains from Sales and Divestitures for Q4 2025 was $1.5 million at Aclaris Therapeutics, up from $608833.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for ACRS hit a ceiling of $1.5 million in Q4 2025 and a floor of $377371.0 in Q1 2021.
  • Median Gains from Sales and Divestitures over the past 5 years was $568940.5 (2024), compared with a mean of $761333.8.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 60.89% in 2022 and later skyrocketed 97.69% in 2024.
  • Aclaris Therapeutics' Gains from Sales and Divestitures stood at $1.3 million in 2021, then plummeted by 60.21% to $533212.0 in 2022, then skyrocketed by 39.77% to $745279.0 in 2023, then skyrocketed by 97.69% to $1.5 million in 2024, then grew by 4.37% to $1.5 million in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $1.5 million (Q4 2025), $608833.0 (Q3 2025), and $595035.0 (Q2 2025) per Business Quant data.